Trimel Announces Exclusive License Agreement With Endo for NATESTO(TM)

TORONTO, ONTARIO--(Marketwired - Nov. 24, 2014) - Trimel Pharmaceuticals Corporation (TSX:TRL) today announced the signing of an agreement by its subsidiary, Trimel Biopharma SRL, providing an affiliate of Endo International plc (NASDAQ:ENDP) (TSX:ENL) with the exclusive rights to market NATESTO™ in the United States and Mexico. NATESTO™ is the first and only FDA-approved testosterone nasal gel indicated for replacement therapy in adult males diagnosed with hypogonadism.

Under the terms of the agreement, Trimel is eligible to receive payments of up to US$165 million based on certain regulatory and sales milestones in addition to an upfront fee of US$25 million and a prepaid inventory deposit of US$5 million upon closing of the deal. Additionally, Trimel will be responsible for the manufacture of NATESTO™ and receive a tiered supply price for the product. Closing of the transaction is subject to customary Hart-Scott-Rodino approval.

"We are delighted to announce this partnership agreement with Endo as it represents another significant achievement for our company and an opportunity to capture the value we have created in developing NATESTO™," said Tom Rossi, President and CEO of Trimel. "Endo is a leader in the U.S. men's health care and urology segments, making them the ideal partner for NATESTO™. We look forward to working with Endo as they prepare to launch this innovative and differentiated treatment option for patients suffering from low testosterone."

Conference Call

Trimel management will host a conference call to discuss the transaction on Monday, November 24, 2014 at 8:30 a.m. Eastern Standard Time. Following the discussion, Trimel executives will address inquiries from investment analysts.

To access the call live, please dial 416-340-8530 or 1-800-952-6845. Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.

A replay of the conference call will be available until 7:00 p.m. Eastern Standard Time on Monday, December 1, 2014 by dialing 905-694-9451 or 1-800-408-3053, using access code: 3080803#.

About NATESTO™ (testosterone) Nasal Gel

Indications and Usage

NATESTO™ is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone including:

• Primary hypogonadism (congenital or acquired)
• Hypogonadotropic hypogonadism (congenital or acquired)

Limitations of Use